Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Gross Profit (2023 - 2025)

Mirum Pharmaceuticals (MIRM) has 3 years of Gross Profit data on record, last reported at $120.7 million in Q4 2025.

  • For Q4 2025, Gross Profit changed N/A year-over-year to $120.7 million; the TTM value through Dec 2025 reached $268.2 million, changed N/A, while the annual FY2025 figure was $421.1 million, 64.97% up from the prior year.
  • Gross Profit reached $120.7 million in Q4 2025 per MIRM's latest filing, up from $69.6 million in the prior quarter.
  • Across five years, Gross Profit topped out at $120.7 million in Q4 2025 and bottomed at $26.6 million in Q1 2023.
  • Average Gross Profit over 3 years is $67.1 million, with a median of $60.5 million recorded in 2024.
  • The widest YoY moves for Gross Profit: up 93.07% in 2024, down 93.07% in 2024.
  • A 3-year view of Gross Profit shows it stood at $26.6 million in 2023, then soared by 161.36% to $69.6 million in 2024, then surged by 73.45% to $120.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Profit were $120.7 million in Q4 2025, $69.6 million in Q3 2024, and $51.4 million in Q1 2024.